Latest Innovation News

Xero Limited reported a robust first half of FY26 with 20% revenue growth and strong cash generation, driven by sustained momentum across its core markets and the strategic Melio acquisition expanding its US footprint.

AUB Group delivered a robust FY25 with a 17.1% rise in underlying net profit and a 15% dividend increase, while navigating a $45 per share acquisition proposal from an EQT-CVC consortium.

Unith Ltd has secured new contracts and expanded its strategic partnerships while advancing its ISO 27001 certification, signaling strong momentum in its AI digital human technology business.

Immutep Limited’s Phase II EFTISARC-NEO trial reveals a novel immunotherapy combo delivering a striking 51.5% tumour response in soft tissue sarcoma patients, alongside robust immune activation signals.

Orica Limited reported a 6% increase in revenue to AUD 8.14 billion and a 23% rise in EBIT to AUD 992.2 million for FY2025, alongside record safety performance and significant strides in decarbonisation.

Xero Limited reports a robust 20% revenue increase in H1 FY26, driven by strong subscriber growth and the strategic Melio acquisition. The company’s innovative AI platform and improved profitability underscore its confident path toward accelerated US market expansion.

Xero Limited reported a robust first half of FY26 with 20% revenue growth and a 42% jump in net profit, driven by the strategic acquisition of Melio and expanded AI capabilities.

Spacetalk Ltd has secured an $877k R&D tax refund for FY2025, more than doubling last year’s amount, underscoring its strategic pivot to software and a 20% growth in recurring revenue.

Reward Minerals has signed a binding Letter of Intent to acquire the Copper Lance Project in Newfoundland, a promising volcanogenic massive sulphide deposit with historic high-grade copper and silver results. The company plans to fast-track exploration to unlock value in this underexplored Canadian terrane.

Australian Vintage reports a modest sales dip in FY25 but charts a clear path to cash flow neutrality and growth through innovation and strategic acquisitions.

The FDA's removal of the black box warning on hormone replacement therapies marks a pivotal shift for Mayne Pharma, potentially unlocking new market opportunities and reshaping women’s health treatment.

Radiopharm Theranostics has successfully enrolled the second cohort in its Phase 1 trial of 177Lu-RAD204, with the Data Safety Monitoring Committee greenlighting a dose increase to 90mCi for the third cohort. Early results show promising tumor targeting and safety in multiple advanced cancers.